Ovensa and Celanese to collaborate to advance precision drug delivery

Themis Medicare gets add on approval for Viralex

Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties

Sinocompound announce new licencing agreement with Dalhousie university

The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University

USFDA approves Novartis Pluvicto to treat prostrate cancer

USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions

Oppilotech and Evariste technologies partner for anti-bacterial programme

Machine learning approach to systems biology combined with ligand discovery platform

Eplontersen granted Orphan Drug Designation in the US

The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US

Sinocompound and InCatT launch new Catalyst Screening Service

This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions

Novartis showcases its attractive growth pipeline

Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint

AIkido updates on use of machine learning in drug development orogram

The goal for the project is the identification and optimization of anti-viral compounds.

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business